Prognostic factors for disease-free survival in postoperative patients with hepatocellular carcinoma and construction of a nomogram model

doi:10.12998/wjcc.v10.i36.13250

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 36

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2699)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-3) series.

Item

Count

PDF

117

WORD

HTML

1146

Figures (1-8)

239

Tables (1-3)

281

Sum=1808

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

190

Download

701

Sum=891

Dec 26, 2022 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Dec 26, 2022; 10(36): 13250-13263
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13250

Table 1 Clinicopathological characteristics of the 344 patients, n (%)

Characteristics	Median (25^th–75^th percentile)
Gender
Male	279 (81.10)
Female	65 (18.90)
Age (yr)
≥ 70	46 (13.37)
< 70	298 (86.63)
Smoking history
Yes	151 (43.90)
No	193 (56.10)
Alcohol consumption history
Yes	133 (38.66)
No	211 (61.34)
History of hepatitis B
Yes	86 (25.00)
No	258 (75.00)
Hypertension
Yes	80 (23.26)
No	264 (76.74)
Diabetes
Yes	41 (11.92)
No	303 (88.08)
BMI
< 18.5	26 (7.56)
≥ 18.5, < 23	160 (46.51)
≥ 23	158 (45.93)
Liver cirrhosis
Yes	256 (74.42)
No	88 (25.58)
Ascites
Yes	44 (12.79)
No	300 (87.21)
Cancer nodules
Single	299 (86.92)
Multiple	45 (13.08)
Capsule
Yes	290 (84.30)
No	54 (15.70)
Tumor diameter
≥ 5 cm	163 (47.38)
< 5 cm	181 (52.62)
Differentiation grade
Low	85 (24.71)
Moderate and High	259 (75.29)
TNM stage
I	262 (76.16)
II	38 (11.05)
III	40 (11.63)
IV	4 (1.16)
Portal vein thrombus
Yes	13 (3.78)
No	331 (96.22)
HBsAg
Positive	268 (77.91)
Negative	76 (22.09)
Surgical method
Proximal stomach	86 (25.00)
Full stomach	258 (75.00)
5-year survival
Yes	162 (47.09)
No	182 (52.91)
Prothrombin time (s)	13.80 (13.30-14.50)
Fibrinogen (g/L)	2.91 (2.41-3.54)
ALB (g/L)	40.45 (37.23-43.78)
TBIL (μmol/L)	10.00 (8.00-15.00)
TC (mmol/L)	4.35 (3.62-4.86)
ALT (U/L)	34.50 (24.00-49.00)
AST (U/L)	36.00 (27.00-52.00)
GGT (U/L)	55.50 (34.00-122.75)
NLR	2.19 (1.64-3.31)
PLR	97.67 (72.10-138.17)

BMI: Body mass index; TNM: Tumor node metastasis; HBsAg: Hepatitis B surface antigen; AFP: Alpha-fetoprotein; ALB: Albumin-bilirubin; TBIL: Total bilirubin; TC: Total cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transpeptidase; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio.

Table 2 Univariate analysis of different factors associated with disease-free survival in hepatocellular carcinoma patients

Characteristics	HR value (95%CI)	P value
Gender
Male	1.00 (reference)
Female	0.840 (0.574, 1.230)	0.371
Age (yr)
< 70	1.00 (reference)
≥ 70	0.577 (0.350, 0.951)	0.031^a
Smoking history
No	1.00 (reference)
Yes	1.031 (0.770, 1.381)	0.839
Alcohol use history
No	1.00 (reference)
Yes	0.813 (0.601, 1.101)	0.182
History of hepatitis B
No	1.00 (reference)
Yes	1.392 (1.008, 1.921)	0.044^a
Hypertension
Yes	1.00 (reference)
No	0.684 (0.471, 0.993)	0.046^a
Diabetes
No	1.00 (reference)
Yes	0.816 (0.513, 1.298)	0.390
BMI
≥ 23	1.00 (reference)
< 23	0.912 (0.682, 1.221)	0.537
Liver cirrhosis
No	1.00 (reference)
Yes	1.321 (0.930, 1.876)	0.120
Ascites
No	1.00 (reference)
Yes	1.172 (0.774, 1.776)	0.453
Cancer nodules
Single	1.00 (reference)
Multiple	1.668 (1.140, 2.497)	0.013^a
Capsule
No	1.00 (reference)
Yes	1.349 (0.925, 1.966)	0.120
Tumor diameter (cm)
< 5	1.00 (reference)
≥ 5	1.350 (1.010, 1.804)	0.043^a
Differentiation grade		0.124
Moderate and High	1.00 (reference)
Low	1.291 (0.932, 1.787)	0.124
TNM stage
I-II	1.00 (reference)
III-IV	1.692 (1.224, 2.340)	0.001^a
Portal vein thrombus
No	1.00 (reference)
Yes	2.862 (1.508, 5.432)	0.001^a
HBsAg
Negative	1.00 (reference)
Positive	1.107 (0.774, 1.582)	0.579
AFP (ng/mL)
≥ 400	1.00 (reference)
< 400	0.958 (0.683, 1.345)	0.805
Fibrinogen (g/L)
≤ 4	1.00 (reference)
> 4	1.494 (1.037, 2.152)	0.031^a
Prothrombin time
Abnormal	1.00 (reference)
Normal	0.836 (0.565, 1.236)	0.369
ALB (g/L)
< 40	1.00 (reference)
≥ 40	0.988 (0.746, 1.335)	0.457
TBIL (μmol/L)
≤ 20.5	1.00 (reference)
> 20.5	1.180 (0.762, 1.827)	0.457
TC (mmol/L)
≤ 5.2	1.00 (reference)
> 5.2	1.401 (0.980, 2.003)	0.065
ALT (U/L)
≤ 50	1.00 (reference)
> 50	1.049 (0.743, 1.481)	0.786
AST (U/L)
≤ 40	1.00 (reference)
> 40	1.055 (0.785, 1.416)	0.724
GTT (U/L)
≤ 60	1.00 (reference)
> 60	1.279 (0.957, 1.709)	0.097
NLR		0.938
< 2.19	1.00 (reference)
≥ 2.19	0.988 (0.740, 1.321)	0.938
PLR
< 97.67	1.00 (reference)
≥ 97.67	0.956 (0.715, 1.277)	0.759

^aP < 0.05.

Table 3 Multivariate analysis of different factors associated with disease-free survival in hepatocellular carcinoma patients

Characteristics	HR value (95%CI)	P value
Age (yr)
< 70	1.00 (reference)
≥ 70	0.543 (0.328, 0.898)	0.017^a
History of hepatitis B
Yes	1.00 (reference)
No	0.654 (0.472, 0.907)	0.011^a
Hypertension
Yes	1.00 (reference)
No	0.754 (0.510, 1.114)	0.156
Cancer nodules (Single/ Multiple)
Single	1.00 (reference)
Multiple	1.009 (0.579, 1.757)	0.975
Tumor diameter (cm)
< 5	1.00 (reference)
≥ 5	1.125 (0.817, 1.548)	0.471
TNM stage
III-IV	1.00 (reference)
I-II	0.585 (0.423, 0.810)	0.001^a
Portal vein thrombus
No	1.00 (reference)
Yes	1.784 (0.885, 3.597)	0.106
Fibrinogen (> 4 g/L/≤ 4 g/L)
≤ 4 g/L	1.00 (reference)
> 4 g/L	1.304 (0.872, 1.951)	0.196

^aP < 0.05.

TNM: Tumor node metastasis.

Citation: Luo PQ, Ye ZH, Zhang LX, Song ED, Wei ZJ, Xu AM, Lu Z. Prognostic factors for disease-free survival in postoperative patients with hepatocellular carcinoma and construction of a nomogram model. World J Clin Cases 2022; 10(36): 13250-13263
URL: https://www.wjgnet.com/2307-8960/full/v10/i36/13250.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i36.13250